EMEA-001214-PIP05-19 - paediatric investigation plan
Benralizumab
PIPHuman
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com
Tel. +46 855326000
P/0388/2021 : EMA decision of 8 September 2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for benralizumab (Fasenra) (EMEA-001214-PIP05-19)